Study on establishment method of cervical squamous cell carcinoma organoid model
Through short-term multiple enzyme digestion and specific medium optimization, the construction success rate and growth cycle of cervical cancer organoids are improved, and the problem of low success rate of cervical cancer organoids in the existing technology is solved, providing a combination of real cervical cancer. Organizationally consistent experimental model that supports efficient drug screening and individualized treatment.
Patent Information
- Application Number
- CN202410880505.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-02
- Publication Date
- 2024-11-08
AI Technical Summary
There is a lack of mature animal models of orthotopic cervical tumors in cervical cancer research. The existing tumor cell lines and PDX models have limitations. The success rate of cervical cancer organoid construction is low, making it difficult to meet the needs of high-throughput drug screening and individualized treatment.
The cervical cancer tissue samples were digested for a short time and multiple times with enzyme-based digestion. After filtration, cells and remaining tissue samples were collected, and cells were cultured in suspension and mixed. The culture medium with a combination of specific growth factors and small molecules was used to support the growth of organoids. Optimize the construction and culture system of cervical carcinoma organoids.
It significantly improves the construction success rate and growth cycle of cervical cancer organoids, ensures that the histochemical and immune performance of organoids is consistent with real cervical cancer tissues, and provides a reliable experimental platform for drug screening and individualized treatment.
Smart Images

Figure CN118909944A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a method for constructing cervical cancer organoids and a culture system thereof, and belongs to the technical field of organoid culture. Background Art
[0002] The morbidity and mortality of cervical cancer rank fourth among female malignant tumors worldwide and is the second most common malignant tumor in Chinese women, posing a serious threat to women's life and health. In scientific research, due to the small cervix of rodents, there is still a lack of mature in situ cervical tumor animal models, which brings challenges to cervical cancer research.
[0003] At present, cervical cancer research mainly relies on tumor cell lines and human tumor tissue xenograft (PDX) models. However, due to the long-term artificial passage of these cell lines, there are limitations in the origin of cervical cancer. In recent years, with the continuous development of various preclinical tumor models, in vitro models represented by organoids (patient-derived organoid, PDO) have shown good application potential in exploring the interaction between tumors and the immune system, evaluating preclinical anti-tumor drugs, and discovering biomarkers for immunotherapy.
[0004] Organoids are multifunctional cell clusters cultured in three dimensions in vitro. They have the ability to self-renew, self-assemble, and maintain the structure and physiological functions of the source tissue. They have been proven to be in vitro models that are highly similar to human organ tissues. Organoids have two major advantages: first, they have the main functional cells in the source tissue; second, they are relatively genetically and phenotypically stable, can be cultured and expanded for a long time, and can be frozen to form a biological sample bank. In 2010, the Clevers team used a 3D-Matrigel culture system containing epidermal growth factor (EGF), Noggin, and R-spondin to culture mouse intestinal crypt cells, forming a crypt villus-like complex of intestinal tissue, thus opening a new chapter in organoid research. In 2011, Sato et al. successfully cultured intestinal adenomas, Barrett's epithelial tissues, and colon cancer tissues using organoid technology, and constructed tumor organoids from tumor patients. In 2013, organoid culture technology was selected as one of the top ten scientific and technological breakthroughs of the year by Science magazine, and was named the technology of the year in the field of life sciences by Nature Methods magazine in 2017. In recent years, organoid-based tumor research has continued to increase. With the improvement of its construction technology and the development of application methods, organoids have become an important tool for oncology and stem cell biology research.
[0005] It is known that clinical gynecological tumors have high heterogeneity, easy drug resistance, high genetic variation and other problems. There is an urgent need for preclinical models that can stably maintain tumor heterogeneity for high-throughput drug screening. Given that organoid models can retain the pathological characteristics and molecular phenotypes of tumor patient tissues and have the advantages of heterogeneity and host genetic background, in recent years, more and more gynecological tumor studies have begun to use organoids for high-throughput drug screening (including drug sensitivity, drug resistance mechanisms, targeted therapy and immunotherapy, etc.) and mechanism research (including the etiology and occurrence and development of malignant tumors, the relationship between malignant tumors and the host's surrounding environment, etc.). However, there are relatively few reports on the construction and application of cervical cancer organoids, and the success rate of cervical cancer organoid construction is low. Therefore, it is urgent to improve the existing construction methods and optimize the culture system in order to provide a reliable model for cervical cancer patient resistance testing and related new drug preclinical research. Summary of the invention
[0006] The present disclosure provides a method for constructing cervical cancer organoids and a culture system thereof. The constructed organoids better retain the characteristics of cervical cancer tissue samples in the human body. The culture system can effectively shorten the growth cycle of cervical cancer organoids and improve the success rate of construction. To this end, the present disclosure proposes the following technical solutions.
[0007] The present invention provides a method for constructing cervical cancer organoids, which comprises the following steps:
[0008] (i) Using enzyme digestion solution to digest cervical cancer tissue samples multiple times in a short time;
[0009] (ii) filtering the digested cervical cancer tissue sample, collecting the filtrate to obtain cells and collecting the remaining tissue sample;
[0010] (iii) performing organoid culture on the collected cells to construct cervical cancer organoids.
[0011] The present invention provides a method for constructing cervical cancer organoids, which comprises the following steps:
[0012] (i) Using enzyme digestion solution to digest cervical cancer tissue samples multiple times in a short time;
[0013] (ii) filtering the digested cervical cancer tissue sample and collecting the remaining tissue sample;
[0014] (iii) performing suspension culture on the remaining collected tissue sample and collecting the cultured cells;
[0015] (iv) performing organoid culture on the collected cells to construct cervical cancer organoids.
[0016] The present invention provides a method for constructing cervical cancer organoids, which comprises the following steps:
[0017] (i) Using enzyme digestion solution to digest cervical cancer tissue samples multiple times in a short time;
[0018] (ii) filtering the digested cervical cancer tissue sample, collecting the filtrate to obtain cells and collecting the remaining tissue sample;
[0019] (iii) performing suspension culture on the remaining collected tissue sample, and collecting the cultured cells from the remaining tissue sample;
[0020] (iv) mixing the cells from steps (ii) and (iii) and performing organoid culture to construct cervical cancer organoids.
[0021] In the scheme of the present invention, "short-term multiple times" or similar expressions refer to multiple short-term enzymatic digestion treatments on cervical cancer tissue samples, and each digestion time does not exceed 10 minutes. Exemplarily, the initial digestion time is 1-3 minutes / time, gradually increasing to 5-7 minutes / time, but each digestion time does not exceed 10 minutes. After each digestion, the state of tissue digestion is observed under a microscope to ensure that the digestion process is moderate and to avoid cell damage. Through this method, two parts of cells can be obtained: cells in the digestion filtrate and cells obtained by suspension culture in the remaining tissue sample. These cells will be mixed together for organoid culture to construct cervical cancer organoids.
[0022] Optionally, before the cervical cancer tissue sample is subjected to the enzyme digestion solution, the tissue sample is washed with a buffer solution containing antibiotics, and the washed tissue sample is cut into small pieces.
[0023] In an embodiment of the present invention, the enzyme digestion solution contains collagenase, which can be any one of type I, type II or type IV collagenase or a combination thereof, with a total concentration of 1-3 mg / mL.
[0024] Furthermore, in the organoid construction process of the present invention, the extraction method of multiple digestions in a short time can effectively reduce the damage to the vitality of primary cells caused by overdigestion. Compared with the digestion process of the prior art, this can greatly reduce the damage to the vitality of cells caused by the digestion process.
[0025] Furthermore, during the suspension culture of the remaining tissue samples, it was found that the cells in the tissue blocks formed regular spheres. Therefore, the tissue block samples can be collected and digested with organoid digestion solution to break the cell spheres into cell clumps, and then the cultured cells from the remaining tissue samples can be collected.
[0026] In an embodiment of the present invention, a proper amount of matrix gel solution can be added to the collected cells and then planted in a well plate. After solidification for a certain period of time, a proper amount of cervical cancer organoid culture medium is added for culture.
[0027] The present invention provides a cervical cancer organoid culture medium, comprising a basal culture medium, a pH adjustment buffer, antibiotics, a cell nutrient supplement, and growth factors and small molecules for regulating cell proliferation and differentiation, for supporting the growth, proliferation and functional maintenance of primary cervical cancer cells.
[0028] Furthermore, the basic components of the culture medium include basic culture medium Advanced DMEM / F-12, pH adjustment buffer HEPES, antibiotics penicillin, streptomycin and primocin.
[0029] To meet the nutritional requirements and growth characteristics of cervical cancer cells, the culture medium also contains cell nutritional supplements, including L-glutamine substitutes GlutaMAX and B27.
[0030] The growth factor combination includes 50-200ng / mL recombinant human Noggin, 30-60ng / mL recombinant human EGF, 50-150ng / mL recombinant human FGF10, and 20-100ng / mL recombinant human FGF7; the small molecule combination includes 250-2000nM A83-01, 5-20μM Forskolin, 5-15μM, SB202190, 2.5-15mM Nicotinamide, 1-5mM N-acetylcysteine, and 5-10μM Y-27632.
[0031] The present disclosure also provides a method for constructing cervical cancer organoids. Exemplarily, the method involves collecting tissue samples from surgical specimens of cervical cancer patients, performing cell separation and culture to construct a cervical cancer organoid model. The present disclosure also conducts a functional evaluation of the constructed cervical cancer organoids to ensure that the histochemical and immune manifestations of the organoids are consistent with real cervical cancer tissues. This method simulates the growth environment of cervical cancer in vivo as closely as possible in vitro, so that the histochemical and immune manifestations of the organoids are consistent with real cervical cancer tissues, providing a reliable experimental platform for subsequent drug development and exploration of treatment methods.
[0032] The present disclosure also provides applications of cervical cancer organoids, such as applications of cervical cancer organoids in drug screening, personalized treatment, etc. By using the organoid model, drugs can be screened and evaluated to verify the efficacy and safety of the drugs; at the same time, personalized treatment research and practice can be carried out according to the individual characteristics and drug sensitivity of the patients, providing more accurate and effective solutions for clinical treatment.
[0033] The present invention makes the cultured cervical cancer organoids closer to the growth and development process of cervical cancer tissue in the human body by carefully designing and optimizing the composition ratio of the culture medium and adding growth factors and small molecules. This better simulates and realistically reflects the characteristics of cervical cancer in the body, providing a more reliable and effective experimental platform for the study of related diseases.
[0034] The culture system provided by the present invention has a good organoid formation rate, and adopts a short-time multiple digestion method instead of a conventional one-time digestion. In addition, the extracted primary cells and the remaining tissue samples are cultured, which further increases the organoid formation rate. Furthermore, the specific growth factor combination and the small molecule combination disclosed in the present invention are used together to regulate the proliferation, differentiation and functional expression of cells, simulate the growth and development process of cervical cancer in vivo, obtain a higher organoid formation rate, and obtain organoids that are very close to human cervical cancer in terms of histochemistry and immunity.
[0035] The cervical cancer organoids provided by the present invention provide researchers with an effective tool for simulating and studying the growth environment of cervical cancer, and provide important support for the development of related drugs and the exploration of treatment methods. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] In order to more clearly illustrate the technical solutions in the embodiments of the present disclosure, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present disclosure. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.
[0037] Figure 1 This is a typical diagram of cervical cancer organoids established under the optimized culture system and their subculture process;
[0038] Figure 2 This is a HE staining comparison of the constructed cervical cancer organoids and the corresponding tissue samples;
[0039] Figure 3 This is the immunofluorescence staining image of the tumor marker Ki67 in the constructed cervical cancer organoid. DETAILED DESCRIPTION
[0040] The principles and features of the present invention are described below, and the examples are only used to explain the present invention and are not used to limit the scope of the present invention. If no specific technology or conditions are specified in the embodiments, the technology or conditions described in the literature in this field or the product instructions are used. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased through regular channels.
[0041] The inventors of the present invention performed the following operations:
[0042] Cell collection and culture: Collect tissue samples from surgical specimens of cervical cancer patients and perform cell isolation;
[0043] Medium preparation: Cervical cancer organoid culture medium is prepared, wherein the basic medium Advanced DMEM / F-12 and other components are added to the culture medium, and the other components include pH adjustment buffer HEPES, a mixed solution of antibiotics penicillin and streptomycin, Primocin, cell nutrition supplements GlutaMAX and B27, and a growth factor combination and a small molecule combination;
[0044] Cell culture: The isolated cervical cancer cells are suspended in a prepared culture medium and cultured under appropriate culture conditions. The concentration and ratio of each component in the culture medium are controlled, as well as other culture conditions such as temperature, humidity and gas environment are optimized to ensure the normal growth and function of the cells;
[0045] Functional assessment:
[0046] Histochemical analysis: Use conventional staining methods (such as H&E staining) to observe the tissue structure and cell morphology of cervical cancer organoids and evaluate their similarity to real cervical cancer tissue.
[0047] In addition, immunohistochemistry (IHC) staining was used to detect the expression of specific proteins (such as KI67) in organoids to further evaluate their activity and function in biological processes.
[0048] Through the above steps, the inventors have worked tirelessly to construct a cervical cancer organoid model similar to human cervical cancer tissue, and verified the similarity of its histological and immunological characteristics, ensuring its reliability and feasibility as a research tool. These evaluation results will provide important support and reference for the exploration of cervical cancer research and treatment methods.
[0049] Therefore, the present inventors have screened and further provided a cervical cancer organoid culture medium, which includes Advanced DMEM / F-12 as a basal culture medium, a pH adjustment buffer HEPES, a mixed solution of antibiotics penicillin and streptomycin, Primocin, cell nutrition supplements GlutaMAX and B27, and a growth factor combination and a small molecule combination, wherein the growth factor combination includes recombinant human Noggin, recombinant human EGF, recombinant human FGF10, and recombinant human FGF7; the small molecule combination includes A83-01, Forskolin, SB202190, niacinamide, N-acetylcysteine and Y-27632.
[0050] Role of growth factors: Growth factors such as recombinant human Noggin, EGF, FGF10 and FGF7 added to the culture medium have important biological functions. They can bind to receptors on the cell surface, activate intracellular signal transduction pathways, and then regulate cell proliferation and differentiation. These growth factors play a key role in simulating the growth of cervical cancer tissues, promoting the growth, spread and invasion of tumor cells.
[0051] The role of small molecules: Small molecules such as A83-01, Forskolin, SB202190, Nicotinamide, N-acetylcysteine and Y-27632 affect the biological characteristics of cells through different mechanisms. For example, SB202190 is a small molecule compound and a selective MAP kinase p38 inhibitor. MAP kinase p38 is a mitogen-activated protein kinase (MAPK) that plays an important role in biological processes such as cell stress response, inflammation and cell cycle regulation. SB202190 can regulate the physiological functions of cells by inhibiting the activity of p38 and affecting multiple cell signaling pathways. In the present invention, it can be combined with other small molecule compounds and combined with a combination of growth factors so that the resulting organoids truly simulate cervical cancer tissue in the human body.
[0052] The role of cell nutrition supplements: Cell nutrition supplements such as GlutaMAX and B27 provide nutrients such as amino acids, vitamins and trace elements required by cells to maintain normal cell growth and metabolism. The precise ratio and concentration control of these nutrients in the culture medium can better meet the growth needs of cervical cancer cells, making the cultured cervical cancer organoids closer to the biological characteristics of cervical cancer tissue in the human body.
[0053] Furthermore, the culture medium of the present invention has the following contents:
[0054] Advanced DMEM / F12
[0055] HEPES concentration: 10-15mM
[0056] Concentration of penicillin-streptomycin mixed solution: 1%-3%
[0057] Primocin concentration: 1%-3%
[0058] GlutaMAX concentration: 1%-3%
[0059] B27 concentration: 0.5%-2%
[0060] Recombinant human Noggin concentration: 50-200ng / mL
[0061] Recombinant human EGF concentration: 30-60ng / mL
[0062] Recombinant human FGF10 concentration: 50-150ng / mL
[0063] Recombinant human FGF7 concentration: 20-100 ng / mL
[0064] A83-01 concentration: 250-2000nM
[0065] Forskolin concentration: 5-20 μM
[0066] SB202190 concentration: 5-15 μM
[0067] Nicotinamide concentration: 2.5-15mM
[0068] N-acetylcysteine concentration: 1-5mM
[0069] Y-27632 concentration: 5-10 μM
[0070] Preferably, the contents of the components in the culture medium are as follows:
[0071] HEPES concentration: 12-14 mM
[0072] Concentration of penicillin-streptomycin mixed solution: 2%-3%
[0073] Primocin concentration: 2%-3%
[0074] GlutaMAX concentration: 2%-3%
[0075] B27 concentration: 1%-2%
[0076] Recombinant human Noggin concentration: 100-150ng / mL
[0077] Recombinant human EGF concentration: 45-55ng / mL
[0078] Recombinant human FGF10 concentration: 75-100 ng / mL
[0079] Recombinant human FGF7 concentration: 40-80ng / mL
[0080] A83-01 concentration: 700-1200nM
[0081] Forskolin concentration: 10-15 μM
[0082] SB202190 concentration: 8-12 μM
[0083] Nicotinamide concentration: 9-12mM
[0084] N-acetylcysteine concentration: 2-3mM
[0085] Y-27632 concentration: 7-9 μM
[0086] Further preferably, the contents of the components in the culture medium are as follows:
[0087] HEPES concentration: 13mM
[0088] Penicillin-streptomycin mixed solution concentration: 2.5%
[0089] Primocin concentration: 2.5%
[0090] GlutaMAX concentration: 2.5%
[0091] B27 concentration: 1.5%
[0092] Recombinant human Noggin concentration: 125ng / mL
[0093] Recombinant human EGF concentration: 50ng / mL
[0094] Recombinant human FGF10 concentration: 87.5ng / mL
[0095] Recombinant human FGF7 concentration: 60ng / mL
[0096] A83-01 concentration: 950nM
[0097] Forskolin concentration: 12.5 μM
[0098] SB202190 concentration: 10 μM
[0099] Nicotinamide concentration: 10.5 mM
[0100] N-acetylcysteine concentration: 2.5mM
[0101] Y-27632 concentration: 8 μM
[0102] The present disclosure also provides the use of both a growth factor combination and a small molecule combination for culturing organoids of cervical cancer, wherein the growth factor combination includes recombinant human Noggin, recombinant human EGF, recombinant human FGF10, and recombinant human FGF7; and the small molecule combination includes A83-01, Forskolin, SB202190, niacinamide, N-acetylcysteine, and Y-27632.
[0103] The present invention provides a method for constructing cervical cancer organoids.
[0104] First, cervical cancer tissue samples are collected from surgical specimens of cervical cancer patients. These tissue samples are obtained from tumor tissues of cervical cancer patients, ensuring that the samples contain only cervical cancer-related cancer cells without surrounding normal tissues. When collecting samples, it is necessary to ensure the freshness and integrity of the specimens to ensure the accuracy and reliability of subsequent experiments.
[0105] Next, through the steps of cell separation and culture, the cervical cancer cells separated from the tissue sample are cultured in the culture medium disclosed in the present invention. In this process, standard cell culture techniques, such as enzyme digestion, centrifugation, etc., are involved to ensure that high-quality and active cervical cancer cells are obtained.
[0106] The organoid model disclosed herein will provide an important experimental platform for cervical cancer-related research, including the study of disease mechanisms, drug screening, and the development of treatment methods.
[0107] After constructing cervical cancer organoids, the present invention further conducted a functional evaluation to ensure that their tissue structure and immune expression were consistent with real cervical cancer tissue.
[0108] The evaluation process includes multiple aspects. First, the tissue morphology of the cervical cancer organoids may be observed and analyzed. This includes using a microscope to examine tissue sections to observe the morphology, arrangement, and characteristics of the tissue structure of the cells. Such an evaluation can reveal whether the tissue structure of the cells inside the organoids is similar to that of real cervical cancer tissue.
[0109] Secondly, immunohistochemistry analysis may be performed on the immune expression of cervical cancer organoids. This involves using specific antibody markers to detect the expression levels of specific proteins in organoids. For example, cancer cell markers, proliferation markers, and signaling pathway molecules associated with cancer development can be detected. Through these analyses, it can be evaluated whether the immune expression of cancer cells in organoids is consistent with real cervical cancer tissue.
[0110] The method disclosed in the present invention can simulate the growth environment of cervical cancer in vivo as much as possible in vitro, and the selection of culture medium is very important. In the process of constructing cervical cancer organoids, specific culture medium is used, which not only provides the nutrients and growth factors required for cell growth, but also simulates the growth microenvironment of cervical cancer in vivo.
[0111] These specific culture media may include essential nutrients, growth factors, and small molecule regulators for the growth and proliferation of cervical cancer cells. These factors are essential for the growth and proliferation of cervical cancer cells, so a reasonable combination in the culture medium can promote the formation and development of cervical cancer organoids.
[0112] By providing culture conditions similar to the in vivo growth environment of real cervical cancer cells, the constructed cervical cancer organoids can be more consistent with real cervical cancer tissues in terms of tissue structure and immune expression. This high similarity provides a reliable experimental platform for subsequent drug development and exploration of treatment methods.
[0113] The cervical cancer organoids provided by the present disclosure have broad application prospects, especially in drug screening and personalized treatment, and are of great significance.
[0114] For drug screening and evaluation, cervical cancer organoids can be used to evaluate the efficacy and safety of candidate drugs. By adding different drugs or drug combinations to the culture medium of cervical cancer organoids, the action process of drugs in cervical cancer tissues in vivo can be simulated. Subsequently, the effects of drugs on cancer cell growth inhibition, apoptosis induction, metastasis and invasion inhibition can be observed to evaluate the efficacy and toxic side effects of drugs. Such drug screening and evaluation processes can help screen out potential therapeutic drugs and provide more options for clinical treatment.
[0115] For personalized treatment research and practice, cervical cancer organoids can also be used to carry out personalized treatment research and practice. By modeling cervical cancer tissue samples from different patients, cervical cancer organoids from different individuals can be obtained. Then, drug sensitivity testing and drug response evaluation can be performed on each patient's organoid model. Such personalized treatment research can help doctors better understand patients' responses to specific drugs and develop personalized treatment plans for each patient. At the same time, it can also help discover new therapeutic targets and personalized treatment strategies to improve treatment effects and prognosis.
[0116] The cervical cancer organoids constructed by the present invention can not only be used for drug screening and evaluation, but also for the research and practice of individualized treatment. This provides a more accurate and effective solution for clinical treatment, and is expected to make an important contribution to improving the treatment effect and survival rate of cervical cancer patients.
[0117] Example 1: Case collection
[0118] The included cervical cancer patients were 10 patients from Zhejiang Cancer Hospital. The following inclusion and exclusion criteria should be met at the same time:
[0119] Inclusion criteria:
[0120] 1) Female, aged ≥18 years old;
[0121] 2) ≤ 65 years old;
[0122] 3) Cervical cancer confirmed by histological pathology;
[0123] 4) Agree to and be able to follow the requirements of this study protocol;
[0124] 5) Subject resources agreed to participate in this study and signed the informed consent form.
[0125] Exclusion criteria:
[0126] 1) Combined with other types of malignant tumors;
[0127] 2) previously received any type of treatment for cervical cancer;
[0128] 3) Other serious diseases that may significantly affect clinical research, such as unstable limbs that require treatment
[0129] 4) Heart disease, kidney disease, chronic hepatitis, poorly controlled diabetes and mental illness, etc.
[0130] Example 2: Sample pretreatment and sample processing
[0131] Sample pretreatment: Use sterilized forceps to transfer the freshly removed cancer tissue to 1xPBS (containing 5% penicillin-streptomycin double antibody solution) to wash and remove blood foam. Then transfer to a 15mL centrifuge tube, add an appropriate amount of 1xPBS (containing 5% penicillin-streptomycin double antibody solution), shake, and perform deep cleaning.
[0132] Sample processing: Use sterile UV-irradiated surgical instruments to cut the tissue into small pieces (about 0.5-1 cm 3 ), a portion of the tissue was randomly taken and frozen at -80°C for sequencing, another portion of the tissue was randomly selected and fixed with 4% paraformaldehyde for histopathological and immunohistochemical analysis, and the remaining tissue was used for organoid construction.
[0133] Add 3mL of tumor tissue digestion solution (Advanced DMEM / F12 solution containing 1mg / ml type I collagenase and 0.2mg / ml DNase) to the tissue, blow several times with a 1mL pipette with the tip cut off, and put it into a shaker at 70-75rpm and 37℃ for digestion. Complete the digestion within 10 minutes, transfer the digested cell suspension to a 50mL centrifuge tube, and add an equal volume of Advanced DMEM / F12 medium containing 5% fetal bovine serum to terminate. At the same time, add 3mL of digestion solution again and repeat the above digestion steps. Check the microscopy in time during digestion until the tissue is completely digested, and end the digestion when almost no cells can be seen.
[0134] Use a 100μm cell sieve to filter all cell suspensions to remove tissue residues in the liquid. Collect the filtrate into a 50mL centrifuge tube and centrifuge at 2000rpm for 5min. If there are many red blood cells in the cell pellet, add red blood cell lysis buffer and treat at room temperature for 3-5min, then add 3 times the volume of advanced DMEM / F12 medium containing 5% fetal bovine serum to dilute and terminate red blood cell lysis. Transfer the cells to a 15mL centrifuge tube, mix well, take 25μL of the cell suspension and mix it with 0.2% trypan blue solution in a volume ratio of 1:1 for cell viability determination and cell counting, and the remaining cell suspension is centrifuged again at 2000rpm for 5min. After the obtained cell pellet is washed once with PBS, repeat the above centrifugation operation and remove the supernatant.
[0135] Example 3: Construction of cervical cancer organoid model
[0136] According to the number of cells, each 30 μL drop of gel contains 1.5x10 5 Add an appropriate amount of matrix gel solution to each cell and plate it in a 24-well plate. The well plate was quickly transferred to a 37°C incubator for solidification for 15 minutes, and then 700 μL of cervical cancer organoid culture medium was added and cultured in a 5% CO2 37°C cell incubator. The liquid culture medium was replaced every 3 days. Among them, the cervical cancer organoid culture medium contains the following components: Advanced DMEM / F12 culture medium, 10mM HEPES buffer, 2% penicillin-streptomycin mixed solution, 2% Primocin, 2% GlutaMAX, 1% B27, 125ng / mL recombinant human Noggin, 50ng / mL recombinant human EGF, 75ng / mL recombinant human FGF10, 40ng / mL recombinant human FGF7, 1μM A83-01, 10μM Forskolin, 10μMSB202190, 10mM nicotinamide concentration, 2.5mM N-acetylcysteine and 5μM Y-27632.
[0137] Example 4: Passaging of organoids
[0138] When the organoid size is above 100μm, the organoid can be digested and passaged. Take out the well-grown organoid from the incubator, mechanically destroy the matrix gel with the culture medium in the well, and transfer it to a pre-cooled 15mL centrifuge tube and centrifuge at 2500rpm for 3min. Discard the upper layer of matrix gel, add 1mL TrypLE to the cell pellet, place it at 37℃ for digestion for 3min, observe under the microscope and find that the organoid is broken, then add 3mL Advanced DMEM / F12 culture medium containing 5% fetal bovine serum to stop digestion, and centrifuge the cell suspension at 2500rpm for 3min. Add 2mL PBS solution to the cell pellet to wash once and centrifuge again. Generally, the organoid is expanded and passaged at a ratio of 1:2 to 1:4. Add an appropriate amount of matrix gel solution to the cell pellet to resuspend the cells. After blowing and mixing, drip 30μL of gel in a 24-well plate, transfer it to a 37℃ incubator to solidify for 15min, and avoid cell adhesion. After the gel drop solidifies, 700 μL of cervical cancer organoid culture medium is slowly added along the wall of the cell culture well, and the cells are cultured in a 5% CO2 37°C cell incubator, with the liquid culture medium replaced every 3 days.
[0139] The results are as follows Figure 1 As shown, the established cervical cancer organoids grew and were passaged well.
[0140] Example 5: Organoid Fixation
[0141] 1) Aspirate the culture medium from the edge of the wells and add 1 mL of 4% paraformaldehyde.
[0142] 2) Gently resuspend the organoids using a 1 mL pipette tip and add the organoid suspension from the desired wells to the same tube. Mix gently and incubate at 4°C for one hour.
[0143] 3) Centrifuge at 4°C for 5 minutes.
[0144] 4) Carefully aspirate and discard the 4% paraformaldehyde.
[0145] 5) Wash with pre-cooled PBS, transfer to an EP tube, centrifuge at 4°C for 5 minutes, and carefully aspirate the PBS. Repeat twice. Resuspend the organoids in pre-cooled 4% paraformaldehyde and incubate at 4°C overnight.
[0146] 6) Place the prepared mold in a culture dish so that it is flush with the bottom and place on ice.
[0147] 7) Gently mix the organoids and centrifuge for 5 minutes. Aspirate the supernatant to avoid contact with the precipitated organoids. (If residual matrix gel is still found, you can also use BD cell recovery medium to incubate on ice for 30 minutes, then centrifuge and aspirate the supernatant to remove the matrix gel as much as possible)
[0148] 8) Melt 2% agarose in boiling water and place in a 65°C water bath.
[0149] 9) Use a 200-pipette pipette tip with the tail cut off to avoid damaging the organoids, and add agarose liquid to gently resuspend the organoids.
[0150] 10) Immediately transfer the resuspended organoid and agarose mixture into a mold on ice.
[0151] 11) Check the number, quality and location of agarose-embedded organoids under an inverted microscope.
[0152] 12) Place on ice for more than 1 hour to ensure that the agarose is completely solidified.
[0153] 13) Pick out the agarose block from the mold, wrap it with moist filter paper and transfer it to a tissue box, store it in 70% ethanol, and proceed to the next step of wax embedding in due course.
[0154] Example 6: Wax block embedding and sectioning
[0155] 1) Dehydration: from low concentration ethanol to high concentration ethanol.
[0156] The sequence was 70% ethanol for 60 min, 80% ethanol for 1 hour, 90% ethanol for 1 hour, 95% ethanol for 1 hour, 95% ethanol for 1 hour, 100% ethanol for 1 hour, and 100% ethanol for 1 hour.
[0157] 2) Transparency: Soak in xylene for 30 minutes (xylene is an organic solvent that can be mixed with alcohol and dissolve paraffin, which allows paraffin to effectively enter the fixed organoids).
[0158] 3) Wax dipping: The process of immersing organoids in melted paraffin after transparency is called wax dipping. It usually takes 2-3 immersions to complete. The melting point of paraffin is 52-56 degrees, and the total time is about 3 hours.
[0159] 4) Embedding: First, add the melted paraffin into the embedding frame, then use hot tweezers to place the organoids into it, making sure the embedding surface is even. After the paraffin solidifies slightly, place it in cold water or a refrigerator to accelerate solidification.
[0160] 5) Slicing: The wax block must go through the steps of trimming, slicing, spreading, scooping, baking, etc., and then be stored in a 4°C refrigerator.
[0161] Example 7: Tissue Embedding
[0162] 1) Aspirate the culture medium from the edge of the wells of the 24-well plate and add 1 mL of 4% paraformaldehyde.
[0163] 2) Use a 1 mL pipette tip to gently resuspend the organoids and add the organoid suspension for the desired wells into the same tube.
[0164] 3) Mix gently and incubate at 4°C for 1 hour.
[0165] 4) Centrifuge at 4°C for 5 minutes.
[0166] 5) Carefully discard the 4% paraformaldehyde, wash with pre-cooled PBS, transfer to a 1.5 mL EP tube, centrifuge at 4°C for 5 minutes, and repeat twice.
[0167] 6) Resuspend in 10% sucrose solution, incubate at 4°C for 1 hour, centrifuge and discard the supernatant, then resuspend in 30% sucrose solution and incubate at 4°C overnight.
[0168] 7) Centrifuge at 4°C for 5 minutes and discard the sucrose solution.
[0169] 8) Add a small amount of optimal cutting temperature compound (OCT) to the sample and let it stand for 15 minutes.
[0170] 9) Transfer the organoids in the EP tube to the freezing embedding mold, continue to add OCT to cover the entire thing and place it in a -20 degree refrigerator until the OCT solidifies. After embedding, it can be stored at -80°C or frozen and sectioned, and then stored at -20°C.
[0171] Example 8 Organoid Function Verification
[0172] 1. Paraffin section HE
[0173] 1) Pre-cool the wax block and cut it into slices of uniform thickness. Place it in a slide box with a water temperature of 45°C and scoop out the slices after they are spread flat.
[0174] 2) After the slices are attached, let them dry slightly, bake them in a 65°C slice oven for 1 hour, and then bake them in an oven for 2 hours to prevent them from falling off in the subsequent steps.
[0175] 3) Dewaxing of sections: xylene I, II, and III for 10 min each; anhydrous ethanol I and II for 5 min; 90% ethanol for 5 min; 80% ethanol for 5 min; 70% ethanol for 5 min; and 50% ethanol for 5 min.
[0176] 4) Staining with hematoxylin solution: Use filter paper to break the oxide film on the surface of the liquid, then stain for 5 minutes (the specific time is adjusted according to the staining results), and rinse with tap water for 5 minutes.
[0177] 5) Differentiate with differentiation solution for 20 seconds (prepared with concentrated hydrochloric acid and 75% alcohol in a ratio of 1:99. This solution needs to be replaced after a period of use. The differentiation time of the new liquid should be shorter. Generally, pull 2-3 times and a light purple-red color can be seen on the glass slide), and rinse with running water for a few seconds.
[0178] 6) Stain with eosin for a few seconds (the specific time will be adjusted according to the staining results), and rinse with running water.
[0179] 7) Dehydrate, seal with neutral gum, and observe under a microscope.
[0180] 2. HE of frozen sections
[0181] For frozen sections, omit the dewaxing step and directly stain after fixation with formalin. The remaining steps are the same as for paraffin sections, but the staining time should be shortened as much as possible.
[0182] The results are as follows Figure 2 As shown, H&E staining to identify the histopathological characteristics of organoids showed that organoids can maintain the morphological characteristics of the original tumor tissue.
[0183] 3. Immunofluorescence staining of tumor marker Ki67
[0184] The wrapped wax block was sliced on a microtome with a thickness of 5 μm; the slices were stretched in a 40°C water bath and collected on glass slides, and dried in a 65°C precision air drying oven for 1 h. The dried slices were dewaxed in xylene and dehydrated with gradient ethanol for later use. The organoid slices were placed in a staining jar containing antigen repair working solution, heated in a constant temperature water bath at 100°C for 15 min, and then naturally cooled at room temperature for antigen repair. The antigen repair working solution in the staining jar was discarded, and PBS was added to wash repeatedly for 3 times; 200 mL of permeabilization solution was added and permeabilization was performed at room temperature for 15 min. The permeabilization solution was discarded, and PBS was added to wash repeatedly for 3 times; excess water was wiped off, and a circle was drawn around the slice with a histochemical pen, and 50 μL of blocking solution was added to the circle, and the block was left to stand at room temperature for 1 h. The blocking solution was discarded, 50 μL of Anti-Ki67 working solution (diluted at a ratio of 1:100) was added to the histochemical circle, and the slices were placed flat in a light-proof humid box and incubated overnight at 4°C. Discard the primary antibody working solution, place the slices in a staining jar, add PBS to wash repeatedly 3 times; wipe off excess water, add 50μL goat anti-rabbit secondary antibody working solution to the tissue circle, place the slices flat in a light-proof humid box, and incubate at room temperature in the dark for 1h. Discard the secondary antibody working solution, place the slices in a staining jar, add PBS to wash repeatedly 3 times; wipe off excess water, add 50μL DAPI working solution to the tissue circle, place the slices flat in a light-proof humid box, and incubate at room temperature in the dark for 10min. Discard the DAPI working solution, place the slices in a staining jar, add PBS to wash repeatedly 3 times; wipe off excess water, add 50μL anti-fluorescence quenching sealing solution to the slide, and cover with a coverslip. Apply nail polish on the four corners of the coverslip, dry in the dark, and observe and photograph under a fluorescence microscope.
[0185] The constructed cervical cancer organoid tumor marker Ki67 immunofluorescence staining is shown in the figure Figure 3As shown in A, B, and C, the results showed that the nuclei of the constructed organoids showed obvious Ki67 positive expression, indicating that they were tumor organoids.
[0186] Example 9
[0187] Cervical Cancer Organoid Culture Medium contains the following components:
[0188] Basic culture medium: Advanced DMEM / F12
[0189] HEPES buffer: 12mM
[0190] Concentration of penicillin-streptomycin mixed solution: 1.5%
[0191] Primocin concentration: 1.5%
[0192] GlutaMAX concentration: 1.5%
[0193] B27 concentration: 0.75%
[0194] Recombinant human Noggin concentration: 100ng / mL
[0195] Recombinant human EGF concentration: 40ng / mL
[0196] Recombinant human FGF10 concentration: 100ng / mL
[0197] Recombinant human FGF7 concentration: 30ng / mL
[0198] A83 01 concentration: 500nM
[0199] Forskolin concentration: 7.5 μM
[0200] SB202190 concentration: 7.5 μM
[0201] Nicotinamide concentration: 5mM
[0202] N-acetylcysteine concentration: 3mM
[0203] Y 27632 concentration: 7.5 μM
[0204] Example 10
[0205] Cervical Cancer Organoid Culture Medium contains the following components:
[0206] Basic culture medium: Advanced DMEM / F12
[0207] HEPES buffer: 15mM
[0208] Penicillin-streptomycin mixed solution concentration: 2.5%
[0209] Primocin concentration: 2.5%
[0210] GlutaMAX concentration: 2.5%
[0211] B27 concentration: 1.5%
[0212] Recombinant human Noggin concentration: 150ng / mL
[0213] Recombinant human EGF concentration: 45ng / mL
[0214] Recombinant human FGF10 concentration: 125ng / mL
[0215] Recombinant human FGF7 concentration: 60ng / mL
[0216] A83 01 concentration: 1000nM
[0217] Forskolin concentration: 15 μM
[0218] SB202190 concentration: 12.5 μM
[0219] Nicotinamide concentration: 7.5mM
[0220] N-acetylcysteine concentration: 4mM
[0221] Y 27632 concentration: 8 μM
[0222] Example 11 The cervical cancer organoid culture medium contains the following components:
[0223] Basic culture medium: Advanced DMEM / F12
[0224] HEPES buffer: 11 mM
[0225] Penicillin-streptomycin mixed solution concentration: 2%
[0226] Primocin concentration: 2%
[0227] GlutaMAX concentration: 2%
[0228] B27 concentration: 1%
[0229] Recombinant human Noggin concentration: 75ng / mL
[0230] Recombinant human EGF concentration: 35ng / mL
[0231] Recombinant human FGF10 concentration: 60ng / mL
[0232] Recombinant human FGF7 concentration: 50ng / mL
[0233] A83 01 concentration: 750nM
[0234] Forskolin concentration: 10 μM
[0235] SB202190 concentration: 10 μM
[0236] Nicotinamide concentration: 6mM
[0237] N-acetylcysteine concentration: 3.5mM
[0238] Y 27632 concentration: 6 μM
[0239] Example 12 The cervical cancer organoid culture medium contains the following components:
[0240] Basic culture medium: Advanced DMEM / F12
[0241] HEPES buffer: 13mM
[0242] Penicillin-streptomycin mixed solution concentration: 1.75%
[0243] Primocin concentration: 1.75%
[0244] GlutaMAX concentration: 1.75%
[0245] B27 concentration: 1.25%
[0246] Recombinant human Noggin concentration: 175ng / mL
[0247] Recombinant human EGF concentration: 50ng / mL
[0248] Recombinant human FGF10 concentration: 140ng / mL
[0249] Recombinant human FGF7 concentration: 80ng / mL
[0250] A83 01 concentration: 1500nM
[0251] Forskolin concentration: 17.5 μM
[0252] SB202190 concentration: 13.5 μM
[0253] Nicotinamide concentration: 12mM
[0254] N-acetylcysteine concentration: 4.5mM
[0255] Y 27632 concentration: 9 μM
[0256] The cervical cancer organoid model was constructed according to Examples 3 and 4, respectively. The culture media of Examples 9-12 can all be used to construct cervical cancer organoids, which enables good growth and passage of the organoids.
[0257] Comparative example: Synergy of growth factor combination and small molecule combination
[0258] Effect of growth factors: Based on Example 3, recombinant human Noggin, EGF, FGF10 or FGF7 were subtracted respectively, 10 organoids were taken and their volumes were measured. It was found that due to the reduction of growth factors, the volume of the organoids was smaller than that of Example 3.
[0259] Effect of small molecules: Based on Example 3, A83-01, Forskolin, SB202190, niacinamide, N-acetylcysteine or Y-27632 were subtracted respectively, and it was found that the average diameter and volume of the constructed organoids were smaller than the diameter of the organoids prepared in Example 3, or some cell morphologies were different from the original tissue cell morphology.
[0260] It can be seen from this that the selection of the growth factor combination and the small molecule combination of the present invention are not the result of arbitrary addition.
[0261] Example 13: Effect of short-term multiple digestion on the success rate of cervical adenocarcinoma culture
[0262] Sample pretreatment and sample processing were performed according to Example 2, and organoid construction was performed according to Example 3. The difference was that the conventional control group was digested for half an hour (corresponding to the volume of digestive fluid: 3X), and the experimental group was digested 3 times, each time for 10 minutes (short-term multiple times). The results showed that the success rate of the conventional control group was 0-40%; while the success rate of the experimental group was greater than 65%.
[0263] Through the high success rate of organoid construction, organoids can be successfully cultured from the patient's primary cervical cancer tissue, providing a reliable model for personalized treatment. Doctors can test multiple drugs on organoids and select the most effective treatment plan, thereby achieving personalized and precise medical services. In addition, large-scale drug screening can be carried out quickly and efficiently. Researchers can screen out potential effective drugs in a short period of time, shorten the drug development cycle, and improve R&D efficiency.
[0264] Embodiment 14
[0265] Sample pretreatment and sample treatment were performed according to Example 2, except that the cells obtained after digestion were collected, and the remaining tissue samples after digestion were suspended and cultured, and then the cultured cells were collected from the remaining tissue samples, and organoid construction was performed according to Example 3.
[0266] The results showed that the success rate of constructing organoids using cells obtained after digestion was about 60-70%; while the success rate of constructing organoids using cells collected and cultured from remaining tissue samples was greater than 85%.
[0267] This result shows that the success rate of remaining tissue sample cells in organoid construction is significantly higher than that of directly using cells obtained after digestion. This means that the remaining tissue samples still retain a large number of cells with high vitality and strong proliferation ability, which helps to improve the efficiency and quality of organoid construction.
[0268] In traditional organoid construction methods, the remaining tissue samples after digestion are usually discarded, resulting in a waste of resources. However, the present invention reuses the remaining tissue samples, which not only improves the cell utilization rate, but also maximizes the retention of cell diversity and integrity in the primary tissue. This is especially important for precious clinical samples, which can make full use of every tissue resource.
[0269] The remaining tissue samples contain more types of cell subpopulations, especially some cells that were not fully released in the initial digestion. These cells can be further released by suspending the remaining tissue samples to increase the diversity and representativeness of cells in organoids. This is of great significance for simulating the complex microenvironment of cervical cancer, studying cancer heterogeneity, and drug screening.
[0270] Due to the high viability of cells in the remaining tissue samples, more functional cells can be obtained through further suspension culture and collection. These cells can grow and differentiate better in organoids, forming a stable and fully functional organoid model. The enhanced stability and functionality of organoids have significant advantages for long-term drug screening and mechanism studies.
[0271] Therefore, using the remaining tissue samples after digestion for cell culture and organoid construction not only significantly improves the success rate, but also reduces resource waste, increases cell diversity and representativeness, and enhances the stability and functionality of organoids. This improved method overcomes the limitation of conventional organoid construction that only uses cells obtained after digestion, and provides a more efficient and reliable platform for precision medicine and drug screening for cervical cancer, which is expected to promote the progress of related research and clinical applications.
[0272] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and cannot be interpreted as limiting the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, it should be understood by those skilled in the art that they can modify, modify or make equivalent substitutions for the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention.
Claims
1. A cervical cancer organoid culture medium, comprising the following components: Basic components, including a basic culture medium (preferably Advanced DMEM / F-12) and a pH regulator to ensure the stability of the culture medium; Antibiotics that inhibit bacteria and fungi, preferably: Penicillin, Streptomycin and Primocin; Cellular nutritional supplements, preferably GlutaMAX and B27; A growth factor combination and a small molecule combination for regulating cell proliferation and differentiation, wherein the growth factor combination includes recombinant human Noggin, recombinant human EGF, recombinant human FGF10, and recombinant human FGF7; and the small molecule combination includes A83-01, Forskolin, SB202190, niacinamide, N-acetylcysteine, and Y-27632.
2. The culture medium according to claim 1, wherein the content is as follows: Advanced DMEM / F12 HEPES concentration: 10-15mM Concentration of penicillin-streptomycin mixed solution: 1%-3% Primocin concentration: 1%-3% GlutaMAX concentration: 1%-3% B27 concentration: 0.5%-2% Recombinant human Noggin concentration: 50-200ng / mL Recombinant human EGF concentration: 30-60ng / mL Recombinant human FGF10 concentration: 50-150ng / mL Recombinant human FGF7 concentration: 20-100 ng / mL A83-01 concentration: 250-2000nM Forskolin concentration: 5-20 μM SB202190 concentration: 5-15 μM Nicotinamide concentration: 2.5-15mM N-acetylcysteine concentration: 1-5mM Y-27632 concentration: 5-10 μM Preferably, the contents of the components in the culture medium are as follows: HEPES concentration: 10-11mM Concentration of penicillin-streptomycin mixed solution: 2%-3% Primocin concentration: 2%-3% GlutaMAX concentration: 2%-3% B27 concentration: 1%-2% Recombinant human Noggin concentration: 100-150ng / mL Recombinant human EGF concentration: 45-55ng / mL Recombinant human FGF10 concentration: 60-80ng / mL Recombinant human FGF7 concentration: 30-50ng / mL A83-01 concentration: 800-1200nM Forskolin concentration: 8-12 μM SB202190 concentration: 8-12 μM Nicotinamide concentration: 9-11mM N-acetylcysteine concentration: 2-3mM Y-27632 concentration: 5-7 μM Further preferably, the contents of the components in the culture medium are as follows: HEPES concentration: 10 mM Penicillin-streptomycin mixed solution concentration: 2% Primocin concentration: 2% GlutaMAX concentration: 2% B27 concentration: 1% Recombinant human Noggin concentration: 125ng / mL Recombinant human EGF concentration: 50ng / mL Recombinant human FGF10 concentration: 75ng / mL Recombinant human FGF7 concentration: 40ng / mL A83-01 concentration: 1000nM Forskolin concentration: 10 μM SB202190 concentration: 10 μM Nicotinamide concentration: 10mM N-acetylcysteine concentration: 2.5 mM Y-27632 concentration: 5 μM.
3. Use of both the growth factor combination and the small molecule combination as defined in claim 1 or 2 in constructing or culturing cervical cancer organoids.
4. Use of the growth factor combination and the small molecule combination defined in claim 1 or 2 in preparing a culture medium for constructing cervical cancer organoids.
5. A method for constructing cervical cancer organoids, comprising using the culture medium defined in claim 1 or 2.
6. Provided is a method for constructing cervical cancer organoids, comprising the following steps: (i) Using enzyme digestion solution to digest cervical cancer tissue samples multiple times in a short time; (ii) filtering the digested cervical cancer tissue sample, collecting the filtrate to obtain cells and collecting the remaining tissue sample; (iii) performing organoid culture on the collected cells to construct cervical cancer organoids.
7. A method for constructing cervical cancer organoids, comprising the following steps: (i) Using enzyme digestion solution to digest cervical cancer tissue samples multiple times in a short time; (ii) filtering the digested cervical cancer tissue sample and collecting the remaining tissue sample; (iii) performing suspension culture on the remaining collected tissue sample and collecting the cultured cells; (iv) performing organoid culture on the collected cells to construct cervical cancer organoids.
8. A method for constructing cervical cancer organoids, comprising the following steps: (i) Using enzyme digestion solution to digest cervical cancer tissue samples multiple times in a short time; (ii) filtering the digested cervical cancer tissue sample, collecting the filtrate to obtain cells and collecting the remaining tissue sample; (iii) performing suspension culture on the remaining collected tissue sample, and collecting the cultured cells from the remaining tissue sample; (iv) mixing the cells from steps (ii) and (iii) and performing organoid culture to construct cervical cancer organoids.
9. The method according to any one of claims 5-8, wherein the culture medium used for the organoid culture is the culture medium according to any one of claims 1-3.
10. The method according to any one of claims 5-8, wherein each digestion time does not exceed 10 minutes, preferably gradually increasing from 1-3 min / time to 5-7 min / time.
11. The method according to any one of claims 5 to 8, wherein the collagenase in the digestion system is any one of type I, type II or type IV collagenase or a combination thereof, and the total concentration is 1-3 mg / mL.
12. A method for drug screening, comprising the step of contacting a drug to be tested with an organoid constructed by the method according to any one of claims 5 to 8.
13. A method for evaluating the effectiveness of a drug, comprising the step of contacting the drug with an organoid constructed by the method according to any one of claims 5 to 8.
14. The method of claim 13, further comprising detecting whether the drug has inhibitory or killing activity on the organoid.
Citation Information
Cited By
3D cell culture method for ultrahigh-resolution subcellular organelle imaging research and application of 3D cell culture method
CN119955707A
3D Cell Culture Method for Ultra-High Resolution Sub-Organelle Imaging Research and Its Application
CN119955707B
